drugset / Trial / NCT00016328

CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme

NCT00016328

Phase 2 Completed 33 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Phase II trial to study the effectiveness of CCI-779 in treating patients who have recurrent glioblastoma multiforme. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Timeline

Start
2001-05
Primary completion
2005-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Temsirolimus Small molecule Intravenous